10-Q: Odyssey Health Reports Q2 2025 Results: Focus Remains on Product Development Amidst Going Concern Uncertainty

Odyssey Health's Q2 2025 report reveals ongoing losses and a focus on securing additional funding to continue operations and product development.

Summary

• Odyssey Health, Inc. filed its Form 10-Q for the quarter ended January 31, 2025.
• The company is focused on developing or acquiring medical-related products, engaging third parties for development, clinical trials, and manufacturing.
• Two technologies are in development: the CardioMap heart monitoring device and the Save a Life choking rescue device.
• The company has not generated any revenues for the year ended July 31, 2024, or the six months ended January 31, 2025, and had an accumulated deficit of $62,242,178 as of January 31, 2025.
• The company's cash available at January 31, 2025, was $7,187, which is insufficient to meet current operating expenses through the third quarter of fiscal 2025.
• The company's ability to continue as a going concern is dependent on raising additional capital.
• Net loss attributable to common shareholders for the six months ended January 31, 2025, was $(1,239,032).
• The company has entered into several amendments to extend the maturity dates of promissory notes with LGH Investments, LLC, and Mast Hill Fund, L.P.
• The company issued a $300,000 promissory note to an accredited investor on August 14, 2024, with an 18% interest rate.
• The company identified material weaknesses in internal control over financial reporting related to insufficient resources and inadequate segregation of duties.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's lack of revenue, significant losses, going concern warning, and material weaknesses in internal control. The company's future is highly uncertain and dependent on securing additional funding.

Positives

• The company is actively seeking additional funding through debt and equity issuances.
• The company is focused on developing medical-related products with potential clinical utility.
• The company is exploring collaborative arrangements with corporate partners.
• The company sold assets for $1,000,000 during the six months ended January 31, 2025.

Negatives

• The company has a significant accumulated deficit of $62,242,178 as of January 31, 2025.
• The company's cash position of $7,187 is insufficient to cover operating expenses through the third quarter of fiscal 2025.
• The company has material weaknesses in internal control over financial reporting.
• The company has a going concern warning.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital, which is not assured.
• The company's products are in development and require FDA clearance or approval to market in the United States.
• The company faces the risk of significant dilution in equity interests if additional equity securities are issued.
• The company's recurring losses, negative cash flow, and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
• The company has material weaknesses in internal control over financial reporting.

Future Outlook

The company's future depends on its ability to raise additional capital through debt or equity issuances or collaborative arrangements with corporate partners.

Industry Context

The company operates in the medical device and product development industry, which is characterized by high regulatory hurdles and significant capital requirements.

Comparison to Industry Standards

• Given the lack of revenue and the going concern warning, Odyssey Health's financial performance is significantly below industry standards for established medical device companies.
• Companies like Medtronic or Johnson & Johnson have substantial revenue streams and strong balance sheets, which contrasts sharply with Odyssey Health's current situation.
• Early-stage medical device companies often rely on venture capital funding and strategic partnerships to advance their products, a path Odyssey Health is attempting to follow.

Related Party Transactions

• The company has related party transactions with officers and directors, including promissory notes and accrued wages.
• As of January 31, 2025, $100,000 of principal and $24,895 of accrued interest related to promissory notes with officers and directors were outstanding.
• The amount of unpaid salary and bonus due to officers was included in accrued wages within the accompanying Condensed Consolidated Balance Sheets and was as follows: Joseph M. Redmond, CEO $1,273,954 and Christine Farrell, CFO $445,617.

Stakeholder Impact

• Shareholders face the risk of significant dilution if additional equity securities are issued.
• Employees face uncertainty due to the company's financial instability.
• Creditors face the risk of non-payment if the company is unable to raise additional capital.

Next Steps

• The company intends to continue seeking additional funding through debt or equity issuances.
• The company plans to continue developing its CardioMap and Save a Life devices.
• The company will determine the most effective method of distribution for each unique product that it includes in its portfolio.

Key Dates